Diabetes Management

Postprandial hyperglycemia

GlycoMark® uniquely monitors hyperglycemia when serum glucose exceeds the renal threshold (180 mg/dL) in moderately controlled patients (HbA1c between 6.5 and 8.5%).
GlycoMark can be used in conjunction with HbA1c. HbA1c is first used to identify moderately controlled patients (6.5 to 8.5%). GlycoMark can then be applied to determine whether the patient is truly in proper control.
GlycoMark differentiates those 40% of moderately controlled patients (HbA1c between 6.5 and 8.5%) who are actually not in good glycemic control.
GlycoMark measures post-meal glucose excursions more effectively than either hemoglobin A1c (HbA1c) or fructosamine. Both HbA1c and fructosamine average both hypo- and hyperglycemia over a 2 - 3 month and 2 - 3 week period, respectively.
GlycoMark targets only hyperglycemia over a 1 - 2 week moving timeframe. In fact, GlycoMark responds to post-meal glucose spikes within 24 - 48 hours.

GlycoMark uniquely reflects post meal (postprandial) hyperglycemia over a short time frame (1 - 2 weeks).
GlycoMark can be used to adjust therapy and diet over the short-term (1 - 2 weeks) rather than waiting for the results of HbA1c testing (2 - 3 months).
The relationship of glucose and 1,5-anhydroglucitol provides a unique opportunity to monitor and control the diet of diabetic patients within a 1 - 2 week timeframe.
GlycoMark is useful for short-term control in patients with elevated hemoglobin A1c values (i.e. > 8.5%). Patients with elevated HBA1cs may actually be in adequate short-term postprandial control if their 1,5-AG is over 10 ug/ml.

Treatment Algorithm and Correlation Charts